TP53 and cancer: Using our established method [9], we assessed the clonality of resistance driver mutations by first correcting VAFs for the influence copy-number states and by subsequently calculating the proportion of cancer cells that harboured resistance driver mutations by comparing against TP53 or APC mutations, which are likely clonal (Table S3).